Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.12 USD
-0.08 (-6.67%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GANX 1.12 -0.08(-6.67%)
Will GANX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Other News for GANX
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Gain Therapeutics Leadership Changes and Executive Compensation
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease